Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.

Cancer research - 1 Aug 2015

Chen Ping, Huhtinen Kaisa, Kaipio Katja, Mikkonen Piia, Aittomäki Viljami, Lindell Rony, Hynninen Johanna, Auranen Annika, Grénman Seija, Lehtonen Rainer, Carpén Olli, Hautaniemi Sampsa

Abstract excerpt

Disseminated high-grade serous ovarian cancer (HGS-OvCa) is an aggressive disease treated with platinum and taxane combination therapy. While initial response can be favorable, the disease typically relapses and becomes resistant to treatment. As genomic alterations in HGS-OvCa are heterogeneous, identification of clinically meaningful molecular markers for outcome prediction is challenging. We developed a novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Bridged-Ring Compounds

Share to CpG Islands

Share to Ovarian Neoplasms

Share to Software

Share to Taxoids

Source

Identifiers

PMID: 26122843
DOI: 10.1158/0008-5472.CAN-14-3242

Genes

HGS
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.PMID 26122843Read ↗

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Prognostic gene expression signature for high-grade serous ovarian cancerSemantic proximity Read ↗

Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles.Semantic proximity Read ↗

Prognostic and predictive value of a mRNA signature in high-grade serous ovarian carcinoma with an integrated computation analysisSemantic proximity Read ↗

Novel gene signatures for prognosis prediction in ovarian cancerSemantic proximity Read ↗

Screening and Identification of a Prognostic Model of Ovarian Cancer by Combination of Transcriptomic and Proteomic DataSemantic proximity Read ↗

Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian CancerSemantic proximity Read ↗

Gene networks and expression quantitative trait loci associated with platinum-based chemotherapy response in high-grade serous ovarian cancerSemantic proximity Read ↗

Identification of prognostic genes after platinum-based chemotherapy in ovarian cancerSemantic proximity Read ↗

Novel regulatory and transcriptional networks associated with resistance to platinum-based chemotherapy in ovarian cancerSemantic proximity Read ↗

Integrative prognostic subtype discovery in high‐grade serous ovarian cancerSemantic proximity Read ↗

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.